Survival outcomes of elderly patients undergoing transcatheter aortic valve implantation after 3 years of follow-up

Table 1 Baseline demographic characteristics, n (%)

Variable	Category	Data
Sex	Male	52 (81.3)
	Female	12 (18.8)
Age in years		88.3 ± 3.6
BMI	Underweight	1 (1.6)
	Normal	12 (18.8)
	Overweight (BMI > 30)	21 (32.8)
	Obese (BMI > 35)	30 (46.9)
Medical history	Diabetes mellitus	39 (60.9)
	Hypertension	51 (79.7)
	Dyslipidemia	31 (48.4)
	Dementia	4 (6.3)
	Rheumatic heart disease	1 (1.6)
	Immunocompromised	0 (0)
	Mediastinal radiotherapy	0 (0)
	Cancer within 5 years	2 (3.1)
	Smoking	6 (9.4)
	Peripheral vascular disease	0 (0)
	ESRD	5 (7.8)
	Dialysis	0 (0)
	Previous cardiac intervention	24 (37.5)
	Previous cardiac surgery	8 (12.5)
	History of MI	16 (25.0)
	Coronary artery disease	34 (53.1)
	Heart failure	10 (15.6)
	Cardiogenic shock	0 (0)
	Atrial fibrillation/flutter	8 (12.5)
	Cerebrovascular disease	5 (7.8)
	Sleep apnea	1 (1.6)
	Liver disease	1 (1.6)
	COPD	3 (4.7)
	Oxygen dependence	1 (1.6)
	Carotid artery disease	1 (1.6)
	Pacemaker insertion	1 (1.6)
	ACE inhibitors/ARBs ≤ 48 hours	27 (42.2)
	First degree heart block	2 (3.1)
	Bundle branch block	4 (6.3)
	Fascicular block	0 (0)
	Second degree heart block	1 (1.6)
Numbers of vessels > 50%	No significant disease	30 (46.9)
	1	14 (21.9)
	2	7 (10.9)
	3	11 (17.2)
NYHA classification	1	5 (7.8)
	2	13 (20.3)
	3	35 (54.7)
	4	10 (15.6)
	Data not available	1 (1.6)
Hematological investigations as mean ± SD	Creatinine (normal range: 44-106 mol/L)	94.02 ± 31.60
	Hematocrit (normal range: 0.42-0.54 L/L)	36.16 ± 6.90
	WBC (normal range: 4-11 × 106 g/L)	6.93 ± 2.40
	Platelets (normal range: 150-400 × 109 g/L)	251.84 ± 86.80

ACE: Angiotensin-converting enzyme; ARBs: Angiotensin II receptor blockers; BMI: Body mass index; COPD: Chronic obstructive pulmonary disease; ESRD: End-stage renal disease; MI: Myocardial infarction; NYHA: New York Heart Association.